Abstract
Hepatitis C virus (HCV) infects an estimated 170 million people globally and persistent infection within the liver is the usual outcome of infection. The resulting liver disease leads to substantial morbidity and to date no vaccine exists. Furthermore the treatments available are frequently ineffective. A minority of those exposed will however successfully control the virus and the factors that dictate this remain elusive. The events that occur in the immediate and early phase post exposure are thought to play a crucial role in determining the outcome and virus specific T cells have a confirmed role in directing the immune response towards a successful outcome. An understanding of the T cell responses and the strategies, which allow the virus to evade these responses in the majority, is an essential prerequisite both for vaccine design and the development of therapeutic agents. We review here the characteristics of the cellular immune responses in acute infection and how the virus manages to undermine these responses and establish chronicity.
Keywords: T cell, acute hepatitis C, immunology, cell-mediated, escape mutation
Current Pharmaceutical Design
Title: Cellular Immunity and Acute Hepatitis C Infection
Volume: 14 Issue: 17
Author(s): K. Fitzmaurice and P. Klenerman
Affiliation:
Keywords: T cell, acute hepatitis C, immunology, cell-mediated, escape mutation
Abstract: Hepatitis C virus (HCV) infects an estimated 170 million people globally and persistent infection within the liver is the usual outcome of infection. The resulting liver disease leads to substantial morbidity and to date no vaccine exists. Furthermore the treatments available are frequently ineffective. A minority of those exposed will however successfully control the virus and the factors that dictate this remain elusive. The events that occur in the immediate and early phase post exposure are thought to play a crucial role in determining the outcome and virus specific T cells have a confirmed role in directing the immune response towards a successful outcome. An understanding of the T cell responses and the strategies, which allow the virus to evade these responses in the majority, is an essential prerequisite both for vaccine design and the development of therapeutic agents. We review here the characteristics of the cellular immune responses in acute infection and how the virus manages to undermine these responses and establish chronicity.
Export Options
About this article
Cite this article as:
Fitzmaurice K. and Klenerman P., Cellular Immunity and Acute Hepatitis C Infection, Current Pharmaceutical Design 2008; 14 (17) . https://dx.doi.org/10.2174/138161208784746806
DOI https://dx.doi.org/10.2174/138161208784746806 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery The Expression of Endotoxic Activity in the Limulus Test as Compared to Cytokine Production in Immune Cells
Current Medicinal Chemistry Neurosarcoidosis
Current Neuropharmacology The Mechanism of Interacting Biologically Active Complexes Dehydroepiandrosterone- or Tetrahydrocortisol-Apolipoprotein A-I with DNA and their Role in Enhancement of Gene Expression and Protein Biosynthesis in Hepatocytes
Current Chemical Biology The Endocannabinoid System and Pain
CNS & Neurological Disorders - Drug Targets The Neuroscience of Maternal Behaviour
Current Psychiatry Reviews Antiviral Medication in Sexually Transmitted Diseases. Part III: Hepatitis B, Hepatitis C
Mini-Reviews in Medicinal Chemistry Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Serum Proteomics for Visceral Leishmaniasis: Promise of Postgenomics Diagnostics for Public Health in Developing Countries
Current Pharmacogenomics and Personalized Medicine PPARδ Signaling Regulates Colorectal Cancer
Current Pharmaceutical Design Synthesis, Hydrolysis Kinetics and Pharmacological Evaluation of Aceclofenac Prodrugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Variety of Interpretation Systems for Human Immunodeficiency Virus Type 1 Genotyping: Confirmatory Information or Additional Confusion?
Current Drug Targets - Infectious Disorders Production of Recombinant Oxytocin Through Sulfitolysis of Inteincontaining Fusion Protein
Protein & Peptide Letters Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Reduction of Anti-HIV-1 Gag Immune Responses During Co-Immunization: Immune Interference by the HIV-1 Envelope
Current HIV Research Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Adrenergic Regulation of Macrophage-Mediated Innate/Inflammatory Responses in Obesity and Exercise in this Condition: Role of β2 Adrenergic Receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets Invasive and Non-invasive Monitoring of Hepatitis C Virus-Induced Liver Fibrosis: Alternatives or Complements?
Current Pharmaceutical Biotechnology Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews